Aethlon Medical raises $4M in latest lifeline for Hemopurifier trials
What's the deal? Aethlon MedicalDealroom has a profile for this one. Try Dealroom → (Nasdaq: AEMD), a San Diego therapeutic company developing treatments for cancer and infectious diseases, priced a $4.0 million follow-on offering on July 6, 2026. Maxim GroupDealroom has a profile for this one. Try Dealroom → acted as sole placement agent on the deal, which was priced at-the-market under Nasdaq rules.
The terms: Aethlon is selling 5,633,009 shares (or pre-funded warrants) plus accompanying warrants at a combined price of $0.7101. The warrants carry a matching exercise price and expire five years after stockholder approval. Closing is expected on or about July 7.
What's the money for? Aethlon plans to use the net proceeds for general corporate purposes, including research and development, clinical trial costs, capital expenditures, and working capital. It may also use part of the proceeds to in-license or acquire complementary technologies.
Why now? This is another quick re-raise in a long run of small capital raises. Aethlon has repeatedly tapped equity markets to fund clinical work on its Hemopurifier device while managing Nasdaq listing pressure.
The pattern: Raises include a $4.7 million public offering in May 2024, a $4.5 million stock-and-warrant offering in September 2025, and a $3.3 million private placement in December 2025. The company has also drawn on an at-the-market equity program, leaving roughly $542,716 of capacity in early June 2026.
What could go wrong? These financings have been accompanied by reverse splits and concerns over a large accumulated deficit and thin cash runway. At $4 million, this deal reads as another incremental lifeline rather than a step-change that materially de-risks the business.
The signal: Aethlon's raises show how small-cap clinical companies lean on repeated equity offerings to keep trials moving and stay listed. Each round buys runway, but the cadence underscores a business still fighting to fund itself.
Read more: Yahoo Finance
Image credit: Generated with Gemini
